Precision Medicine in Oncology®

Douglas A. Levine, MD, shared his insight on how the ovarian cancer landscape has developed a more personalized treatment approach.

Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.

Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.

John Mendelsohn, MD, served as president of The University of Texas MD Anderson Cancer Center for a 15-year period that saw that institution’s size triple and its budget quadruple.